What Do Industry Leaders Think?
Industry leaders provide feedback on serialization and anti-
counterfeiting—shining light on where pharma is headed as
well as the industry’s greatest vulnerabilities.
By Bob Miglani, Chief of Business Development, Applied DNA Sciences
How beneficial will pharmaceutical serialization be to manufacturers and patients? With serialization now set to impact the industry in the form of a key
component of the Drug Supply Chain Security Act
(DSCSA), its potential value is worth exploring in
detail. The prime motivation behind serialization—
to help protect patients from exposure to drugs
that may be counterfeit, stolen, contaminated,
or otherwise harmful—is clearly of critical
importance. Any system designed to improve the
detection and removal of potentially dangerous
drugs from the drug supply chain is worthwhile.
What has been missing to date from the
serialization initiative, however, are the personal
perspectives and opinions of those on the front
lines: the executives and other leaders in the
pharmaceutical industry who will be in charge
of putting it into practice. In a recent survey, the
rosy picture painted by the backers of serialization
is tempered somewhat, revealing a landscape of
expectations that are decidedly more mixed. The
survey results provide a useful set of insights for
everyone involved in this enterprise.